Ahead-of print articles
- Page Path
- HOME > Articles and issues > Ahead-of print articles
Articles in E-pub version are posted online ahead of regular printed publication.
Newsletter
- What’s new in kidney tumor pathology 2022: WHO 5th edition updates
- Maria Tretiakova
- Received August 13, 2022 Accepted August 16, 2022 Published online September 8, 2022
- DOI: https://doi.org/10.4132/jptm.2022.08.16 [Epub ahead of print]
- 400 View
- 93 Download
-
Abstract
PDF - The 5th edition WHO Classification of Urinary and Male Genital Tumours (2022) introduces significant changes relevant to daily practice, especially in the completely restructured renal cell tumor chapters. Herein we highlight the most important diagnostic updates of known kidney tumor types, new and molecularly defined entities and emerging/provisional entities.
Original Article
- Expression of specific microRNAs in tissue and plasma in colorectal cancer
- Allan Fellizar, Vivencio Refuerzo, John Donnie Ramos, Pia Marie Albano
- Received October 27, 2021 Accepted February 19, 2022 Published online May 3, 2022
- DOI: https://doi.org/10.4132/jptm.2022.02.19 [Epub ahead of print]
- 1,024 View
- 146 Download
-
Abstract
PDF
- Background
MicroRNAs (miRNA/miR) play significant roles in the regulation of cell differentiation, cell cycle progression, and apoptosis. They become dysregulated during carcinogenesis and are eventually released into the circulation, enabling their detection in body fluids. Thus, this study compared the miRNA expression in tissue and plasma samples of colorectal cancer (CRC) patients and clinically healthy controls and determined miRNA expression as a potential CRC biomarker.
Methods
Using quantitative reverse transcription polymerase chain reaction (RT-qPCR), miR-21-5p, miR-29a-3p, miR-92a-3p, miR-135b-5p, miR-196b-5p, and miR-197-3p, expression was analyzed and compared between the malignant (n = 41) and the adjacent neoplasm free mucosal tissues (n = 41) of CRC patients. The findings were validated in plasma samples (n = 36) collected from the same CRC patients prior to surgery or any form of treatment and compared to plasma from their age and sex-matched controls (n = 36).
Results
MiR-21-5p, miR-29a-3p, miR-92a-3p, and miR-196b-5p were upregulated and miR-135b-5p was downregulated in CRC malignant tissues compared to their expression in adjacent neoplasm-free tissue. This was further observed in the plasma of the same CRC cases compared to controls. MiR-92a-3p showed itself the most sensitive (0.93; p < .001) and most specific (0.95; p < .001) in detecting CRC in tissue. In plasma, miR-196b-5p was the most sensitive (0.97; p < .001) and specific (0.94; p < .001) in detecting CRC. Plasma miR-92a-3p and miR-196b-5p were the most sensitive (0.95; p < .001) and specific (0.94; p < .001) in the early detection of CRC.
Conclusions
Results show that specific miRNAs dysregulated in malignant tissues are released and can be detected in the circulation, supporting their potential as non-invasive biomarkers of CRC.
First
Prev
